Dividend Raise Fails to Mask Structural Headwinds

What happened

Amgen announced a 6% dividend increase, signaling continued commitment to shareholder returns. However, this comes as the company faces mounting pressures: acquisition-related debt from the Horizon deal, accelerating declines in legacy drugs like ENBREL and Prolia due to IRA price cuts and biosimilar competition, and a significant capital commitment to its obesity program (MariTide). Filings show ENBREL net price fell 38% in Q3 2025, Otezla took a $1.2B impairment, and leverage remains elevated with net debt/EBITDA over 4x. Despite these headwinds, management is prioritizing the dividend, which may constrain financial flexibility as it simultaneously funds capex (~$2.6B in 2026), R&D, and debt reduction. The news article argues the dividend raise masks a tougher road ahead, aligning with our analysis that the stock's premium valuation leaves little buffer for execution shortfalls.

Implication

The dividend increase is unlikely to change the fundamental outlook; the core issues of legacy erosion, policy pressure, and leverage remain. With shares trading near $339, the risk-reward is skewed negative, as the market already prices in significant growth from newer drugs and MariTide. Income investors may find the yield attractive, but total return could suffer if the stock corrects toward our $295 attractive entry. We recommend trimming positions above $370 and waiting for a pullback below $300 to reassess, especially if obesity data disappoint. The dividend decision may also signal management's confidence in cash flows, but we would want to see sustained deleveraging and legacy stabilization before becoming more constructive.

Thesis delta

The report already flagged debt, legacy declines, and obesity bet. The dividend raise does not alter the thesis; if anything, it confirms management's commitment to returning cash despite pressures, which could be viewed as either disciplined or potentially reckless if cash flows deteriorate. No change to our POTENTIAL SELL rating; we maintain our view that better entry points are likely.